Selected research
Industry Research
Human Immunodeficiency Virus (HIV) Industry Research Report 2026
Market perspective
The global Human Immunodeficiency Virus (HIV) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Human Immunodeficiency Virus (HIV) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Human Immunodeficiency Virus (HIV) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Human Immunodeficiency Virus (HIV) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Human Immunodeficiency Virus (HIV) include Merck & Co., Inc., Mylan, AbbVie, ViiV Healthcare, Genentech, Inc., Genentech, Inc., Cipla, Inc., Bristol-Myers Squibb Company and Boehringer Ingelheim GmbH and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Human Immunodeficiency Virus (HIV) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Human Immunodeficiency Virus (HIV).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Immunodeficiency Virus (HIV) Market by Company
Merck & Co., Inc.
Mylan
AbbVie
ViiV Healthcare
Genentech, Inc.
Genentech, Inc.
Cipla, Inc.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH
Human Immunodeficiency Virus (HIV) Segment by Type
Protease Inhibitors
NNRTIs
Coreceptor Antagonists
NRTIs
Entry and Fusion Inhibitors
Integrase Inhibitors
Human Immunodeficiency Virus (HIV) Segment by Application
Clinics
Hospitals
Labs
Human Immunodeficiency Virus (HIV) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunodeficiency Virus (HIV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Immunodeficiency Virus (HIV) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunodeficiency Virus (HIV).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human Immunodeficiency Virus (HIV) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Protease Inhibitors
- NNRTIs
- Coreceptor Antagonists
- NRTIs
- Entry and Fusion Inhibitors
- Integrase Inhibitors
Applications
- Clinics
- Hospitals
- Labs
Companies covered
- Merck & Co., Inc.
- Mylan
- AbbVie
- ViiV Healthcare
- Genentech, Inc.
- Genentech, Inc.
- Cipla, Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Boehringer Ingelheim GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Human Immunodeficiency Virus (HIV) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Protease Inhibitors
- 2.2.3 NNRTIs
- 2.2.4 Coreceptor Antagonists
- 2.2.5 NRTIs
- 2.2.6 Entry and Fusion Inhibitors
- 2.2.7 Integrase Inhibitors
- 2.3 Human Immunodeficiency Virus (HIV) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinics
- 2.3.3 Hospitals
- 2.3.4 Labs
- 2.4 Assumptions and Limitations
3 Human Immunodeficiency Virus (HIV) Breakdown Data by Type
- 3.1 Global Human Immunodeficiency Virus (HIV) Historic Market Size by Type (2021-2026)
- 3.2 Global Human Immunodeficiency Virus (HIV) Forecasted Market Size by Type (2027-2032)
4 Human Immunodeficiency Virus (HIV) Breakdown Data by Application
- 4.1 Global Human Immunodeficiency Virus (HIV) Historic Market Size by Application (2021-2026)
- 4.2 Global Human Immunodeficiency Virus (HIV) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Human Immunodeficiency Virus (HIV) Market Perspective (2021-2032)
- 5.2 Global Human Immunodeficiency Virus (HIV) Growth Trends by Region
- 5.2.1 Global Human Immunodeficiency Virus (HIV) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Human Immunodeficiency Virus (HIV) Historic Market Size by Region (2021-2026)
- 5.2.3 Human Immunodeficiency Virus (HIV) Forecasted Market Size by Region (2027-2032)
- 5.3 Human Immunodeficiency Virus (HIV) Market Dynamics
- 5.3.1 Human Immunodeficiency Virus (HIV) Industry Trends
- 5.3.2 Human Immunodeficiency Virus (HIV) Market Drivers
- 5.3.3 Human Immunodeficiency Virus (HIV) Market Challenges
- 5.3.4 Human Immunodeficiency Virus (HIV) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Human Immunodeficiency Virus (HIV) Players by Revenue
- 6.1.1 Global Top Human Immunodeficiency Virus (HIV) Players by Revenue (2021-2026)
- 6.1.2 Global Human Immunodeficiency Virus (HIV) Revenue Market Share by Players (2021-2026)
- 6.2 Global Human Immunodeficiency Virus (HIV) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Human Immunodeficiency Virus (HIV) Head Office and Area Served
- 6.4 Global Human Immunodeficiency Virus (HIV) Players, Product Type & Application
- 6.5 Global Human Immunodeficiency Virus (HIV) Manufacturers Established Date
- 6.6 Global Human Immunodeficiency Virus (HIV) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Human Immunodeficiency Virus (HIV) Market Size (2021-2032)
- 7.2 North America Human Immunodeficiency Virus (HIV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Human Immunodeficiency Virus (HIV) Market Size by Country (2021-2026)
- 7.4 North America Human Immunodeficiency Virus (HIV) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Human Immunodeficiency Virus (HIV) Market Size (2021-2032)
- 8.2 Europe Human Immunodeficiency Virus (HIV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Human Immunodeficiency Virus (HIV) Market Size by Country (2021-2026)
- 8.4 Europe Human Immunodeficiency Virus (HIV) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Human Immunodeficiency Virus (HIV) Market Size (2021-2032)
- 9.2 Asia-Pacific Human Immunodeficiency Virus (HIV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Human Immunodeficiency Virus (HIV) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Human Immunodeficiency Virus (HIV) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Human Immunodeficiency Virus (HIV) Market Size (2021-2032)
- 10.2 South America Human Immunodeficiency Virus (HIV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Human Immunodeficiency Virus (HIV) Market Size by Country (2021-2026)
- 10.4 South America Human Immunodeficiency Virus (HIV) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Human Immunodeficiency Virus (HIV) Market Size (2021-2032)
- 11.2 Middle East & Africa Human Immunodeficiency Virus (HIV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Human Immunodeficiency Virus (HIV) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Human Immunodeficiency Virus (HIV) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck & Co., Inc.
- 12.1.1 Merck & Co., Inc. Company Information
- 12.1.2 Merck & Co., Inc. Business Overview
- 12.1.3 Merck & Co., Inc. Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.1.4 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.1.5 Merck & Co., Inc. Recent Developments
- 12.2 Mylan
- 12.2.1 Mylan Company Information
- 12.2.2 Mylan Business Overview
- 12.2.3 Mylan Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.2.4 Mylan Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.2.5 Mylan Recent Developments
- 12.3 AbbVie
- 12.3.1 AbbVie Company Information
- 12.3.2 AbbVie Business Overview
- 12.3.3 AbbVie Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.3.4 AbbVie Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.3.5 AbbVie Recent Developments
- 12.4 ViiV Healthcare
- 12.4.1 ViiV Healthcare Company Information
- 12.4.2 ViiV Healthcare Business Overview
- 12.4.3 ViiV Healthcare Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.4.4 ViiV Healthcare Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.4.5 ViiV Healthcare Recent Developments
- 12.5 Genentech, Inc.
- 12.5.1 Genentech, Inc. Company Information
- 12.5.2 Genentech, Inc. Business Overview
- 12.5.3 Genentech, Inc. Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.5.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.5.5 Genentech, Inc. Recent Developments
- 12.6 Genentech, Inc.
- 12.6.1 Genentech, Inc. Company Information
- 12.6.2 Genentech, Inc. Business Overview
- 12.6.3 Genentech, Inc. Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.6.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.6.5 Genentech, Inc. Recent Developments
- 12.7 Cipla, Inc.
- 12.7.1 Cipla, Inc. Company Information
- 12.7.2 Cipla, Inc. Business Overview
- 12.7.3 Cipla, Inc. Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.7.4 Cipla, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.7.5 Cipla, Inc. Recent Developments
- 12.8 Bristol-Myers Squibb Company
- 12.8.1 Bristol-Myers Squibb Company Company Information
- 12.8.2 Bristol-Myers Squibb Company Business Overview
- 12.8.3 Bristol-Myers Squibb Company Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.8.4 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.8.5 Bristol-Myers Squibb Company Recent Developments
- 12.9 Boehringer Ingelheim GmbH
- 12.9.1 Boehringer Ingelheim GmbH Company Information
- 12.9.2 Boehringer Ingelheim GmbH Business Overview
- 12.9.3 Boehringer Ingelheim GmbH Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.9.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.9.5 Boehringer Ingelheim GmbH Recent Developments
- 12.10 Boehringer Ingelheim GmbH
- 12.10.1 Boehringer Ingelheim GmbH Company Information
- 12.10.2 Boehringer Ingelheim GmbH Business Overview
- 12.10.3 Boehringer Ingelheim GmbH Revenue in Human Immunodeficiency Virus (HIV) Business (2021-2026)
- 12.10.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Product Portfolio
- 12.10.5 Boehringer Ingelheim GmbH Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst